Neil Palmisiano

1.5k total citations
64 papers, 491 citations indexed

About

Neil Palmisiano is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Neil Palmisiano has authored 64 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 24 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Neil Palmisiano's work include Acute Myeloid Leukemia Research (26 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Acute Lymphoblastic Leukemia research (10 papers). Neil Palmisiano is often cited by papers focused on Acute Myeloid Leukemia Research (26 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Acute Lymphoblastic Leukemia research (10 papers). Neil Palmisiano collaborates with scholars based in United States, China and India. Neil Palmisiano's co-authors include Margaret Kasner, Lindsay Wilde, Ranjana H. Advani, Brad S. Kahl, Catherine Diefenbach, Stephen M. Ansell, Richard F. Ambinder, Jonathon B. Cohen, Kevin A. David and Fangxin Hong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Neil Palmisiano

56 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Neil Palmisiano United States 13 228 162 156 128 120 64 491
Harald Biersack Germany 13 242 1.1× 196 1.2× 219 1.4× 116 0.9× 71 0.6× 33 560
Raya Mawad United States 13 214 0.9× 264 1.6× 127 0.8× 52 0.4× 98 0.8× 38 459
Danielle Shafer United States 12 151 0.7× 118 0.7× 169 1.1× 85 0.7× 48 0.4× 30 398
Sylvain Garciaz France 11 117 0.5× 133 0.8× 113 0.7× 69 0.5× 64 0.5× 46 324
Yoshitomo Maesako Japan 10 115 0.5× 91 0.6× 105 0.7× 173 1.4× 97 0.8× 21 370
M.V. Mateos Spain 9 286 1.3× 358 2.2× 269 1.7× 132 1.0× 78 0.7× 15 557
William Larry Gluck United States 8 172 0.8× 66 0.4× 111 0.7× 94 0.7× 155 1.3× 24 409
Haerim Chung South Korea 12 93 0.4× 122 0.8× 123 0.8× 81 0.6× 73 0.6× 46 352
Ángel Ramírez Páyer Spain 12 263 1.2× 177 1.1× 162 1.0× 116 0.9× 286 2.4× 33 609
Rama Al Hamed France 9 223 1.0× 308 1.9× 236 1.5× 71 0.6× 53 0.4× 11 487

Countries citing papers authored by Neil Palmisiano

Since Specialization
Citations

This map shows the geographic impact of Neil Palmisiano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Palmisiano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Palmisiano more than expected).

Fields of papers citing papers by Neil Palmisiano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Palmisiano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Palmisiano. The network helps show where Neil Palmisiano may publish in the future.

Co-authorship network of co-authors of Neil Palmisiano

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Palmisiano. A scholar is included among the top collaborators of Neil Palmisiano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Palmisiano. Neil Palmisiano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Palmisiano, Neil, et al.. (2025). Transition to Survivorship Care for Adolescents and Young Adults (AYAs) with Acute Leukemia: Provider Perspectives. Journal of Adolescent and Young Adult Oncology. 14(5). 434–441.
2.
Zayac, Adam, et al.. (2025). Lymphoma and leukemia occurring during pregnancy. Seminars in Perinatology. 49(2). 152041–152041. 1 indexed citations
3.
Palmisiano, Neil, Ju‐Whei Lee, David F. Claxton, et al.. (2024). A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. SHILAP Revista de lepidopterología. 5(5). 951–956. 1 indexed citations
4.
Wilde, Lindsay, Patrizia Porazzi, Rossana Trotta, et al.. (2023). A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Leukemia Research. 129. 107075–107075. 4 indexed citations
5.
Palmisiano, Neil, Grace R. Jeschke, Lindsay Wilde, et al.. (2023). A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancers. 15(21). 5129–5129.
6.
7.
Ferrarotto, Renata, Paul Swiecicki, Dan P. Zandberg, et al.. (2023). PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. Oral Oncology. 149. 106634–106634. 19 indexed citations
8.
Badar, Talha, Ehab Atallah, Rory M. Shallis, et al.. (2023). Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy. Blood. 142(Supplement 1). 592–592. 3 indexed citations
9.
Grosso, Dolores, Benjamin E. Leiby, Lindsay Wilde, et al.. (2022). A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation. Transplantation and Cellular Therapy. 28(12). 831.e1–831.e7. 3 indexed citations
10.
Feng, Yang, et al.. (2022). miR-196b–TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A -Mutant AML. Clinical Cancer Research. 28(20). 4574–4586. 13 indexed citations
11.
Badar, Talha, Mark R. Litzow, Rory M. Shallis, et al.. (2022). Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer. 129(6). 934–945. 5 indexed citations
12.
Wilde, Lindsay, et al.. (2022). Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. Frontiers in Oncology. 12. 892289–892289. 3 indexed citations
13.
Thomas, Colin, et al.. (2021). Efficacy of Half-Day Workshops for Internal Medicine Interns in Educating Breaking-Bad-News Discussions. SHILAP Revista de lepidopterología. 2(1). 132–136. 2 indexed citations
14.
Diefenbach, Catherine, Fangxin Hong, Richard F. Ambinder, et al.. (2020). Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. The Lancet Haematology. 7(9). e660–e670. 97 indexed citations
15.
Binder, Adam, Nathan Handley, Lindsay Wilde, Neil Palmisiano, & Ana Mariá López. (2020). Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize Care. Frontiers in Oncology. 10. 1183–1183. 17 indexed citations
16.
Kasner, Margaret, et al.. (2019). A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 37(15_suppl). TPS7065–TPS7065. 3 indexed citations
17.
McBride, Amanda, Lindsay Wilde, Carlos E. Vigil, et al.. (2019). The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome. Frontiers in Oncology. 9. 192–192. 32 indexed citations
18.
Grosso, Dolores, Önder Alpdoğan, Joanne Filicko-O’Hara, et al.. (2017). The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT). Blood. 130. 1959–1959. 1 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harald Biersack Breakdown of academic impact, for papers by Raya Mawad Breakdown of academic impact, for papers by Danielle Shafer Breakdown of academic impact, for papers by Sylvain Garciaz Breakdown of academic impact, for papers by Yoshitomo Maesako Breakdown of academic impact, for papers by M.V. Mateos Breakdown of academic impact, for papers by William Larry Gluck Breakdown of academic impact, for papers by Haerim Chung Breakdown of academic impact, for papers by Ángel Ramírez Páyer Breakdown of academic impact, for papers by Rama Al Hamed
Rankless by CCL
2026